Last updated: September 24, 2026
Hepatitis B immune globulin intravenous (human), principally represented by HepaGam B, is a specialized plasma-derived biologic used mainly to prevent recurrent hepatitis B infection after liver transplantation. Its market is small, hospital-based and supply constrained rather than mass-market. Revenue depends on liver-transplant volumes, hepatitis B prevalence among transplant recipients, plasma collection capacity, reimbursement and long-term manufacturing continuity.
Standalone product revenue is not publicly reported by the principal manufacturers. The commercial outlook is therefore best assessed through clinical demand, product concentration, regulatory barriers, competing HBIG products and manufacturer disclosures rather than audited brand-level sales.
What is hepatitis B immune globulin intravenous (human)?
Hepatitis B immune globulin intravenous (human) is a purified human plasma-derived immunoglobulin containing antibodies against hepatitis B surface antigen. The product provides passive immunity and is used when immediate antibody protection is required.
HepaGam B is the principal U.S. product associated with intravenous HBIG use. The FDA approved HepaGam B in 2007 for prevention of hepatitis B virus recurrence in liver-transplant recipients who are hepatitis B surface-antigen positive and have undergone transplantation for hepatitis B-related liver disease.[1]
The product is administered in a controlled clinical setting. Treatment generally involves an initial dose during the transplant procedure followed by repeated dosing based on the product label and the treating center’s protocol. Long-term antiviral therapy is also commonly used in transplant patients, limiting HBIG demand to a defined high-risk population rather than all patients with chronic hepatitis B.
Product profile
| Attribute |
Hepatitis B immune globulin intravenous (human) |
| Principal U.S. brand |
HepaGam B |
| Active ingredient |
Human hepatitis B immune globulin |
| Biological source |
Human plasma from screened donors |
| Primary U.S. use |
Prevention of recurrent HBV infection after liver transplantation |
| FDA approval pathway |
Biologics license application |
| FDA approval year for HepaGam B |
2007 |
| Main purchasers |
Transplant hospitals, specialty pharmacies and hospital distributors |
| Administration |
Intravenous use in the transplant setting; product labeling also addresses other administration routes and uses |
| Substitution pattern |
Physician- and hospital-directed; no conventional automatic generic substitution |
| Market structure |
Specialty, concentrated and supply-sensitive |
How large is the hepatitis B immune globulin market?
The addressable market is limited by the number of liver-transplant recipients requiring HBV prophylaxis. The broader hepatitis B population is much larger, but most patients with chronic hepatitis B do not receive HBIG. Nucleos(t)ide analogues, including tenofovir and entecavir, are the principal long-term antiviral treatments for chronic HBV.
The relevant commercial population consists of:
- Liver-transplant recipients with current or prior HBV infection.
- Selected patients requiring post-exposure prophylaxis.
- Newborns of hepatitis B surface-antigen-positive mothers, where HBIG is generally administered intramuscularly rather than intravenously.
- Individuals requiring protection after occupational, sexual or household exposure.
The transplant segment drives the value of intravenous HBIG because treatment is repeated, expensive and delivered through specialist centers. U.S. liver-transplant activity has remained structurally supported by organ-allocation improvements, advances in transplant medicine and expanded use of donation after circulatory death. The HBV-positive share of recipients has declined in many developed markets because antiviral therapy suppresses viral replication before transplantation and reduces recurrence risk after surgery.
Demand drivers
| Driver |
Effect on market |
| Liver-transplant volume |
Increases the number of potential HBIG-treated patients |
| HBV-related transplant burden |
Determines the core recurring-use population |
| Antiviral prophylaxis |
Can reduce HBIG intensity or duration in some protocols |
| Hospital procurement |
Concentrates purchasing power and increases price scrutiny |
| Plasma availability |
Constrains supply and limits rapid market expansion |
| Product shortages |
Can shift demand between brands and increase inventory purchasing |
| Clinical guidelines |
Determine whether centers use finite-course or extended prophylaxis |
| Reimbursement |
Affects hospital willingness to maintain inventory |
What is the financial trajectory for HepaGam B and intravenous HBIG?
The financial trajectory is likely stable to moderately positive in nominal terms, but it is not a conventional high-growth pharmaceutical market. Pricing can rise because plasma collection, fractionation and quality-control costs are high. Unit demand is more likely to track transplant activity and treatment protocols than broad HBV prevalence.
Manufacturers generally do not disclose HepaGam B revenue separately in annual reports. Product-level revenue is usually combined with other plasma-derived products, immunoglobulins or specialty pharmaceuticals. This prevents a reliable public calculation of annual sales, margins or market share.
Revenue profile
The product has several characteristics that support revenue durability:
- High clinical switching costs in transplant care.
- Limited number of qualified plasma-derived suppliers.
- Product-specific regulatory requirements.
- Need for validated viral inactivation and removal processes.
- Hospital reliance on continuous supply.
- Recurring dosing for certain transplant patients.
The principal financial risks are different from those affecting small-molecule brands. Generic erosion is limited, but supply disruption, donor-plasma constraints, manufacturing deviations and hospital price negotiations can reduce revenue.
A plausible commercial trajectory is:
| Period |
Likely market condition |
| Near term |
Stable demand with pricing and supply-chain sensitivity |
| Medium term |
Low single-digit volume growth tied to transplant activity, offset by declining HBV incidence and antiviral substitution |
| Longer term |
Persistent specialty demand, but increasing protocol pressure to reduce HBIG exposure where clinical outcomes permit |
The most material upside would come from broader use in transplant protocols or new prophylactic indications. The most material downside would come from clinical adoption of HBIG-sparing regimens, improved antiviral control and loss of manufacturing reliability.
What is the FDA regulatory status of intravenous HBIG?
HepaGam B is an FDA-approved biologic regulated under a biologics license application. The product is not a conventional chemically synthesized drug and is not treated like a standard abbreviated new drug application product.
The FDA-approved transplant indication gives the product a defined clinical role, but the label does not create a broad monopoly over all use of hepatitis B immune globulin. Hospitals may use other licensed HBIG products when clinically appropriate and available.
FDA regulation focuses on:
- Donor eligibility and infectious-disease testing.
- Plasma pooling and traceability.
- Viral inactivation and removal.
- Batch consistency.
- Potency and antibody content.
- Manufacturing-site compliance.
- Postmarketing safety reporting.
Because HBIG is plasma-derived, the manufacturing process and source material are central to regulatory value. A rival cannot enter simply by copying the active ingredient. It must establish qualified plasma supply, a validated purification process, adequate clinical support and a compliant biologics manufacturing system.
What patents protect hepatitis B immune globulin intravenous (human)?
The commercial protection for intravenous HBIG is primarily regulatory and manufacturing-based rather than dependent on a conventional blockbuster patent estate.
HepaGam B is approved as a biologic and is not generally protected through the Orange Book patent-listing framework used for drugs approved under section 505 of the Federal Food, Drug, and Cosmetic Act. Biologic reference products are tracked through the FDA Purple Book, while patent disputes are handled under the Biologics Price Competition and Innovation Act framework.[2,3]
Patent and exclusivity assessment
| Protection category |
Relevance to intravenous HBIG |
| Orange Book patents |
Generally not the primary protection mechanism for a BLA biologic |
| Purple Book listing |
Relevant to reference-product and biosimilar status |
| Regulatory exclusivity |
Important, but original approval exclusivity has expired |
| Formulation patents |
May exist at the manufacturer or process level, but are not the main barrier |
| Method-of-use patents |
Could cover particular prophylaxis protocols, but clinical use is driven largely by approved labeling and practice standards |
| Manufacturing know-how |
High importance |
| Plasma supply agreements |
High importance |
| Facility qualification |
High importance |
| Biosimilar competition |
Possible in principle, but difficult and not currently a major visible threat |
No broad, active patent monopoly should be assumed for the underlying HBIG molecule. The stronger barriers are plasma sourcing, process validation, regulatory history, hospital contracts and reliable batch supply.
When does hepatitis B immune globulin lose exclusivity?
The principal U.S. regulatory exclusivity period for an older biologic such as HepaGam B has expired. The FDA approved the product in 2007, while the BPCIA generally provides 12 years of reference-product exclusivity for qualifying biologics. That period would have elapsed by approximately 2019, subject to the specific statutory treatment of the product and FDA reference-product status.[3]
Patent expiry is not the decisive commercial date because the product’s principal barrier is not a single composition-of-matter patent. A competing manufacturer would still need to obtain its own approval and demonstrate manufacturing, quality and clinical comparability.
There is no conventional “generic launch date” for HepaGam B comparable to the date used for a small-molecule drug. A rival would more likely enter through a separate biologics license, a biosimilar pathway if legally and scientifically appropriate, or an alternative licensed HBIG product.
What is the Orange Book and Purple Book status of HepaGam B?
HepaGam B should be analyzed as a biologic rather than as an Orange Book-centered pharmaceutical product. The FDA Purple Book identifies licensed biological products and provides the framework for biosimilar and interchangeable-product analysis.[2]
The commercial implications are:
- No automatic pharmacy substitution based on a generic equivalent.
- No standard Paragraph IV pathway against an Orange Book-listed patent.
- No routine Abbreviated New Drug Application competition.
- Greater importance of FDA manufacturing review and product-specific clinical evidence.
- Hospital procurement decisions remain central even after regulatory exclusivity expires.
Are there Paragraph IV challenges to intravenous HBIG?
Paragraph IV litigation is not the expected challenge pathway for HepaGam B because Paragraph IV certifications apply to patents listed in the Orange Book for products approved under the drug-approval provisions of the FD&C Act.
A competitor seeking to challenge HepaGam B would more likely pursue:
- A standalone BLA for an HBIG product.
- A biosimilar application, if the product qualifies under the statutory framework.
- A separate product with comparable clinical use.
- A regulatory or patent challenge focused on manufacturing, formulation or a particular method of use.
No material public Paragraph IV litigation is associated with HepaGam B as the core product. The absence of Paragraph IV cases does not eliminate competition risk; it indicates that competition would arise through biologics development and manufacturing rather than the standard generic-drug litigation model.
What biosimilar risk exists for intravenous HBIG?
Biosimilar risk is currently limited by the complexity of plasma-derived polyclonal immunoglobulin products. HBIG contains a heterogeneous antibody population generated from human plasma pools. Demonstrating analytical and clinical similarity is more complex than reproducing a single monoclonal antibody or small molecule.
Key barriers include:
- Variability in donor plasma.
- Antibody potency and specificity.
- Viral clearance validation.
- Consistency across production lots.
- Clinical comparability.
- Reference-product availability.
- Cost of establishing a qualified plasma network.
- Limited market size relative to development expense.
A biosimilar or follow-on product could still emerge if the reference market supports adequate pricing. The most realistic competitive threat is a licensed alternative HBIG product with equivalent clinical utility, not rapid automatic substitution at the pharmacy level.
Which companies compete with intravenous HBIG?
Competition includes manufacturers of intravenous or intramuscular HBIG products, depending on indication and route.
| Company or product group |
Competitive relevance |
| HepaGam B |
Key U.S. product for post-liver-transplant HBV recurrence prevention |
| Grifols and HyperHEP B S/D |
Competes mainly in intramuscular HBIG indications |
| Kedrion and related plasma-derived products |
Potential regional or product-level competition depending on market |
| Other national HBIG suppliers |
Relevant where licensed, imported or hospital-procured |
| Antiviral manufacturers |
Indirect competitors because antiviral prophylaxis can reduce HBIG use |
The market is segmented by route, indication, country and hospital protocol. An intramuscular product is not automatically a direct substitute for an intravenous transplant product, even if both contain hepatitis B immune globulin.
What licensing deals, litigation and settlements affect the market?
No major publicly disclosed licensing transaction, settlement agreement or patent litigation has established a new U.S. entrant against HepaGam B as the central commercial issue.
The more important transaction risks are likely to involve:
- Acquisition of plasma-collection assets.
- Manufacturing or fill-finish arrangements.
- Regional commercialization rights.
- Hospital distribution contracts.
- Supply agreements with transplant centers.
- Transfers of biologics manufacturing sites.
For this product class, a manufacturing acquisition can be commercially more important than a patent license. Control of plasma supply and an approved production facility can determine market access.
How strong is the patent estate and manufacturing position?
The patent estate is less important than the manufacturing position. A strong commercial position depends on four assets:
- A licensed product with an accepted transplant indication.
- Reliable access to suitable human plasma.
- A validated purification and viral-clearance process.
- Consistent supply to transplant hospitals.
This creates a defensible but nonexclusive market position. The product can retain pricing power after regulatory exclusivity ends, but it remains exposed to alternative licensed products, hospital tenders and HBIG-sparing clinical protocols.
What generic launch risks exist?
A conventional generic launch risk is low. The principal risks are:
- Entry by an alternative licensed HBIG product.
- A biosimilar or follow-on biologic.
- Hospital switching driven by shortages or price.
- Clinical protocols that reduce treatment duration.
- New antiviral regimens that reduce recurrence risk.
- Manufacturing or inspection interruptions.
- Reimbursement changes affecting transplant-center purchasing.
The probability of an abrupt, high-volume generic erosion event is lower than for a small molecule with an expired composition patent. Revenue erosion would more likely be gradual and account-specific.
How does intravenous HBIG compare with antiviral prophylaxis?
HBIG and antiviral therapy are complementary rather than identical products. HBIG provides passive antibodies, while antivirals suppress HBV replication. Current transplant management often uses combination prophylaxis, but the amount and duration of HBIG vary by patient risk and institutional protocol.[4]
| Factor |
Intravenous HBIG |
Oral antiviral prophylaxis |
| Mechanism |
Passive antibody protection |
Suppression of viral replication |
| Delivery |
Hospital or specialist administration |
Oral outpatient treatment |
| Supply risk |
Plasma and biologics manufacturing |
Chemical or tablet manufacturing |
| Cost structure |
High unit and administration cost |
More scalable outpatient cost |
| Commercial exposure |
Concentrated in transplant centers |
Broad chronic-HBV population |
| Substitution risk |
Protocol-driven |
Competes indirectly by reducing HBIG need |
The competitive pressure from antivirals is the largest long-term demand risk. It reduces the number of patients requiring prolonged HBIG, even when HBIG remains part of the initial transplant protocol.
Key Takeaways
- Hepatitis B immune globulin intravenous (human) is a specialty biologic market centered on liver-transplant prophylaxis.
- HepaGam B is the principal U.S. product associated with intravenous HBIG use.
- Standalone brand revenue is not publicly disclosed, so financial analysis depends on transplant volumes, treatment protocols and manufacturer-level reporting.
- Regulatory exclusivity has expired, but conventional generic substitution and Paragraph IV litigation are not the main risks.
- Biosimilar entry is technically difficult because the product is a plasma-derived polyclonal immunoglobulin.
- Manufacturing know-how, plasma supply, viral-clearance validation and hospital access are more important than a broad composition-of-matter patent.
- Antiviral prophylaxis and HBIG-sparing transplant protocols create the main long-term volume risk.
- The commercial outlook is stable but specialized, with limited volume growth and potential price support from supply constraints.
FAQs
Is HepaGam B a vaccine?
No. HepaGam B is a passive immunoglobulin product containing hepatitis B antibodies. It does not create the active immune response associated with hepatitis B vaccination.
Can a pharmacy automatically substitute another HBIG product for HepaGam B?
Generally no. HBIG products are biologics with product-specific approvals, routes and indications. Hospital physicians and transplant protocols typically determine product selection.
Is intravenous HBIG used for routine chronic hepatitis B treatment?
No. Routine chronic hepatitis B management generally relies on antiviral therapy. Intravenous HBIG is used primarily in defined prophylactic settings, especially after liver transplantation.
Does HBIG have biosimilar competition in the United States?
No major U.S. biosimilar threat has become commercially established for intravenous HBIG. Development is constrained by the complexity of plasma-derived polyclonal immunoglobulin manufacturing and the limited size of the transplant market.
What is the most important investment risk for an HBIG manufacturer?
The primary risks are manufacturing interruption, plasma scarcity, hospital price pressure and declining HBIG intensity in transplant protocols. Patent expiration is a less important risk than it is for conventional small-molecule drugs.
References
- U.S. Food and Drug Administration. (2007). HepaGam B prescribing information. FDA.
- U.S. Food and Drug Administration. (n.d.). Purple Book: Database of licensed biological products. FDA.
- U.S. Congress. (2010). Biologics Price Competition and Innovation Act of 2009, Public Law 111-148, §7002.
- Terrault, N. A., Lok, A. S. F., McMahon, B. J., Chang, K.-M., Hwang, J. P., Jonas, M. M., Brown, R. S., Jr., Bzowej, N. H., & Wong, J. B. (2018). Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology, 67(4), 1560-1599.
